Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00615212 · ClinicalTrials.gov registry record · Phase 1

Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects

A Phase 1 study, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 1
Development phase
23
Enrollment target

NCT00615212: Completed Phase 1 study, sponsored by GlaxoSmithKline.

NCT00615212 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 23 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00615212, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 1
Development phase
23 participants
Enrollment target

Study Summary

This study is meant to assess potential inhibitory effects of GSK376501 on CYP450 isoenzymes 3A4, 2C8, 2C9. subjects will receive probe compounds and systemic levels of these substrates will be compared pre and post dosing of GSK376501.

Interventions

  • DRUG Midazolam
  • DRUG Rosiglitazone
  • DRUG Flurbiprofen
  • DRUG GSK376501

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2008-01-02
Est. Completion 2008-02-15
Phase Phase 1
GlaxoSmithKline

1,345 total trials

What the finished NCT00615212 record still lists

NCT00615212 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower).

The record links to 0 conditions, and to 4 interventions - of which Midazolam is the first listed.

NCT00615212 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00615212 about?

NCT00615212 is a clinical study titled "Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects". This study is meant to assess potential inhibitory effects of GSK376501 on CYP450 isoenzymes 3A4, 2C8, 2C9. subjects will receive probe compounds and systemic levels of these substrates will be compared pre and post dosing of GSK376501.

What is the current status of trial NCT00615212?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2008-01-02. Estimated completion is 2008-02-15.

What interventions are being tested in trial NCT00615212?

The interventions under investigation include: Midazolam (DRUG), Rosiglitazone (DRUG), Flurbiprofen (DRUG), GSK376501 (DRUG).

Who is sponsoring clinical trial NCT00615212?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00615212's enrollment target sits among peer trials

23 1596th of 2000 higher than 400 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00615212, the US trial registry maintained by the National Library of Medicine. NCT00615212 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.